Low-Calorie Diet Safe and Effective for Gestational Diabetes, Reduces Insulin Need: Study Finds

UK: A study in Nature Medicine found that a 1,200-calorie diet per day was safe and effective for pregnant women with gestational diabetes and a BMI of at least 25, significantly reducing the need for long-acting insulin therapy.

The researchers note that gestational diabetes affects 6–15% of pregnancies worldwide and increases health risks for both mother and baby. Overweight, obesity, and excessive weight gain during pregnancy are key risk factors. While weight loss improves blood sugar control in non-pregnant people with type 2 diabetes, its role in gestational diabetes remains unclear. Although international guidelines recommend weight gain based on BMI, studies suggest that lower weight gain or even weight loss may benefit women with gestational diabetes. However, there is little research on effective dietary strategies for managing weight in this group, highlighting the need for further studies on safe energy intake.

To fill this knowledge gap, Claire L. Meek, Cambridge Universities NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK, and colleagues aimed to determine whether losing weight during pregnancy can improve health outcomes for mothers and babies with gestational diabetes.

For this purpose, the researchers conducted a multicenter, randomized, double-blind trial to examine the effects of energy restriction in pregnant women with gestational diabetes and a BMI of 25 or higher. Participants were randomly assigned to either a standard 2,000-calorie diet or a reduced 1,200-calorie diet from 29 weeks of pregnancy until delivery. Diets were provided weekly with a balanced composition of 40% carbohydrates, 35% fat, and 25% protein. Randomization followed a 1:1 ratio, stratified by center and blinded to participants and the study team. The primary outcomes measured were maternal weight change by 36 weeks and newborn birth weight.

The key findings of the study were as follows:

  • At 36 weeks, maternal weight change and standardized birth weight showed no significant differences between the groups.
  • The reduced-energy diet group had a lower need for long-acting insulin therapy than the standard-energy diet group (27.5% versus 39.2%; OR 0.36).
  • Weight loss of approximately 3 kg in late pregnancy improved maternal blood sugar levels, lowered systolic blood pressure, and reduced the incidence of large-for-gestational-age infants.
  • The occurrence of small-for-gestational-age infants was similar in both groups and remained within expected limits.
  • There were no stillbirths, neonatal deaths, or maternal deaths in the reduced-energy diet group.

The findings showed that for women with gestational diabetes and a BMI ≥ 25 kg/m², incorporating a 1,200 kcal/day diet into evidence-based guidelines should be considered. This approach was found to be safe during pregnancy and effectively reduced the need for initiating long-acting insulin therapy.

“A safe and effective way to achieve energy restriction during pregnancy is through a low-glycemic-index diet, incorporating ample vegetables, lean protein, and some dairy products to ensure adequate nutrient intake,” the researchers wrote.

Reference:

Kusinski, L. C., Jones, D., Atta, N., Turner, E., Smith, S., Oude Griep, L. M., Rennie, K., Sharp, S. J., Farewell, V., Murphy, H. R., Taylor, R., & Meek, C. L. (2025). Reduced-energy diet in women with gestational diabetes: The dietary intervention in gestational diabetes DiGest randomized clinical trial. Nature Medicine, 31(2), 514-523. https://doi.org/10.1038/s41591-024-03356-1

Powered by WPeMatico

Even lower doses of Ethambutol can Induce Optic Neuropathy, suggests study

Even lower doses of Ethambutol can Induce Optic Neuropathy, suggests a study published in the Cureus.

The present study aims to determine the incidences of ethambutol-induced optic neuropathy (EON) and its associated risk factors in Central Indian tertiary care centers. A single-centered retrospective observational study was conducted. Data was collected from the Directly Observed Therapy Short-course (DOTS) centre after implementing the revised National Tuberculosis Control Program (RNTCP) 2016 guidelines. The collected data included demographic data, history of underlying diseases, such as diabetes mellitus, hypertension, HIV infection, and history of smoking. The site of tuberculosis infection, daily dose, ethambutol (EMB) treatment duration, onset, and type of ocular symptoms were recorded. We performed regression analyses to investigate the univariate and multivariable associations with different variables. Results: Of the 1676 patients who received ethambutol for TB treatment, 987 had an ophthalmological symptom unrelated to EON, and 13 developed EON (incidence =0.28%). Demographic and clinical variables considered were age, gender, race/ethnicity, body mass index (BMI), and diabetes mellitus status. Examples of current infection information were chronic HIV and other comorbidities uniquely associated with renal function site/type treatment specific dose/duration ethambutol. Longer treatment duration significantly correlates with greater thickness of the left temporal retinal nerve fibre layer (RNFL) and thicker average RNFL. Increased peripapillary retinal nerve fibre layer (pRNFL) thickness on the left nasal RNFL scan was significantly correlated with ethambutol tablets (or count) (p=0.027). The findings indicate that ethambutol toxicity is indeed dose and duration-dependent, evidenced by the relationship between prolonged treatment and increased RNFL thickness, suggesting heightened risk of visual impairment. Moreover, adverse effects were observed at even lower doses (12.3 mg/kg), reinforcing that no dose of ethambutol is entirely safe.

Reference:

Singh P, Karkhur S, Verma V (February 17, 2025) Ethambutol-Induced Optic Neuropathy: A Retrospective Study of Incidences and Risk Factors. Cureus 17(2): e79160. doi:10.7759/cureus.79160

Keywords:

Even, lower, doses, Ethambutol, can, Induce, Optic, Neuropathy, suggests, study, ethambutol, ethambutol-induced optic neuropathy (eon), revised national tuberculosis control programme (rntcp), rnfl thickness, tuberculosis, Singh P, Karkhur S, Verma V

Powered by WPeMatico

False Advertising, misrepresentation: CCI Clears Hospital In Unregistered Surgeon Row

New Delhi: The Competition Commission of India (CCI) has dismissed a complaint filed against Victor Hospital, Margao, Goa, regarding allegations of misleading consumers by employing an unregistered surgeon and engaging in anti-competitive practices.

Presiding over the case, Ravneet Kaur, Chairperson; Sweta Kakkad, Member; Deepak Anurag, Member clarified that the allegations against Victor Hospital did not raise concerns under competition law. The commission stated that misleading consumers by misrepresenting a surgeon’s qualifications and engaging in false advertising, while serious, do not amount to anti-competitive behaviour under the Competition Act, 2002. It was noted that such issues should be dealt with by medical regulatory bodies rather than the CCI.

The case, filed by Moses Pinto, claimed that the hospital’s actions distorted market competition and violated Sections 3 and 4 of the Competition Act, 2002. However, the CCI, in its order dated March 3, 2025, found that the claims did not warrant an investigation.

The complaint stemmed from an incident on August 1, 2023, when Pinto was admitted to Victor Hospital for suspected acute appendicitis. The hospital, under the care of Dr Rajesh S Javherani, recommended a Laparoscopic Appendectomy, which was performed by Dr P Ravi Teja. Post-surgery, the patient allegedly suffered severe complications, including an enterocutaneous fistula, which later required corrective surgery at BLK-MAX Hospital, New Delhi.

During the second surgery, doctors reportedly discovered that a portion of the appendix and a fecalith had been left behind during the first operation. As a result, 10 cm of the patient’s small intestine had to be resected to rectify the damage. Pinto claimed that the surgical errors caused him physical suffering and financial hardship.

Furthermore, during a Goa Medical Council disciplinary inquiry, it was revealed that Dr Teja did not possess a valid registration with the council at the time of performing the surgery. The council ruled on July 19, 2024, that Dr Teja had practised without valid registration for over 10 months, violating the National Medical Commission Act, 2019. The council imposed a penalty of Rs10,000 on the surgeon but did not take action against the hospital itself.

In his complaint to the CCI, the patient alleged that Victor Hospital’s continued employment and promotion of Dr Teja as a “Consultant Surgeon” despite his lack of credentials amounted to unfair market practices. He argued that the hospital gained an unlawful competitive advantage by misrepresenting its staff qualifications, thereby attracting patients under false pretences. Pinto also claimed that compliant healthcare providers incurred higher costs by hiring properly registered professionals, while Victor Hospital circumvented these regulations to cut costs and attract more patients.

Pinto accused Victor Hospital of engaging in misleading advertising by falsely presenting Dr Teja as a registered consultant, thereby attracting patients under false pretences. He further claimed that the hospital gained an unfair competitive advantage over other healthcare providers that followed regulatory standards and employed only registered practitioners. Additionally, the patient argued that the hospital compromised patient safety by allowing an unqualified practitioner to perform surgeries, potentially endangering lives. Lastly, he asserted that such practices undermined consumer trust and distorted market dynamics by creating an uneven playing field for compliant hospitals.

However, after reviewing the complaint, the CCI ruled that these allegations did not raise any competition law concerns. The commission observed;

“The alleged deliberate misleading of consumers through misrepresentation of the qualifications of its surgeon and engagement in false advertising by the Opposite Party (Victor Hospital) do not raise any competition issue under the provisions of the Act.”

The CCI further noted that while the claims may be relevant for consumer protection and medical regulatory bodies, they do not fall under the purview of competition law. The commission concluded;

“In view of the foregoing and in the facts and circumstances of the present matter, the Commission is of the view that there is no prima-facie case of contravention of provisions of the Act warranting an investigation into the matter.”

Based on its findings, the CCI ordered the closure of the case under Section 26(2) of the Competition Act, 2002, stating that no case arose for granting relief under Section 33. The commission also directed its secretary to communicate the decision to the complainant.

To view the original order, click on the link below:

Powered by WPeMatico

NBE to Open Final NEET SS 2024 Application edit Window, check details

New Delhi- The National Board of Examinations in Medical Sciences (NBEMS) is soon going to open the final application correction window for all the applicants who have registered for the National Eligibility Entrance Test-Super Specialty (NEET SS) for the academic year 2024-25.

The NEET SS 2024 final form correction window will open on March 11, 2025, and close on March 13, 2025.

Candidates can process the final correction window through online mode from the NBE official website. However, it is to be noted that after the final editing window closes, no edits will be acceptable to the information provided in the application form. In the final NEET SS 2024 correction window, candidates can rectify the Deficient or Incorrect Images such as Photographs, Signatures and Thumb Impressions. NBE has recently concluded the NEET SS 2024 form correction window. 

STEPS TO EDIT FINAL NEET SS 2024 APPLICATION

STEP 1- Visit the official website of NBE.

STEP 2- Select the ‘NEET SS’ tab from the homepage and then click on the ‘Application Link.’

STEP 3- Click on the ‘Login’ tab displayed on the screen.

STEP 4- Add the user ID and password and enter the given security code.

STEP 5- Modify the permitted fields as per the requirement

STEP 6- Carefully verify all changes before submitting the NEET SS application form.

Meanwhile, after the completion of the final NEET SS 2024 edit window process, NBE will be issuing the Admit Card on 25th March 2025. As per the official schedule, the NEET SS 2024 exam will be conducted on March 29 and 30, 2025. Whereas, the result is expected to be declared by April 30, 2025. The online NEET SS 2024 application submission process began on 4th February 2025, at 3 PM onwards and concluded on 24th February 2025 at 11:55 PM. 

Also Read: Want to Pursue DM and DrNB in Infectious Diseases? Check Out NEET SS feeder Qualification

Powered by WPeMatico

Vying for DM or DrNB In Paediatric Neurology? Check out feeder Qualifications

New Delhi: For the NEET SS 2024 aspirants seeking admission to DM/DrNB Paediatric Neurology, MD/DNB (Paediatrics) has been designated as the feeder qualifications.

DM/DrNB Paediatric Neurology or Doctorate of Medicine /Doctorate of National Board in Paediatric Neurology is a super speciality level course for doctors in India that is done by them after completion of their postgraduate medical degree course. The duration of this super speciality course is 3 years, and it focuses on the diagnosis and treatment of congenital heart diseases and coronary artery diseases in children.

 As per the information bulletin released by the National Board of Examinations (NBE), the feeder qualification for DM/DrNB Paediatric Neurology is MD/DNB (Paediatrics) defined by the NBE and is subject to changes by the NBE.

The eligibility criteria for DM/DrNB Paediatric Cardiology are defined as the set of rules or minimum prerequisites that aspirants must meet in order to be eligible for admission, which include:

Name of course Course Type Prior Eligibility Requirement
Paediatric Neurology DM/DrNB MD/DNB (Paediatrics)

NEET SS 2024:

ELIGIBILITY CRITERIA

The applicant must meet/fulfil the following criteria-

1 Candidates who have a recognized postgraduate medical Degree/Provisional Pass Certificate (MD/MS/DNB) or equivalent recognized qualification or are likely to have the same by 30th April 2025 by eligible feeder speciality qualifications for super speciality courses as mentioned in Annexure B of this Information Bulletin can apply for NEET-SS 2024.

2 Candidates found to be ineligible at any stage of NEET-SS 2024 will not be permitted to appear in the examination. In the unlikely event of any ineligible candidate appearing and/or being successful in NEET-SS 2024, the result/ candidature of such candidate shall be cancelled and/or is deemed to be cancelled as and when the ineligibility is detected.

3 The cutoff date for qualifying MD/MS/DNB Broad Specialty/ eligible feeder qualification towards determination of eligibility for appearing in NEET-SS 2024 shall be 30th April 2025.

4 Requests for appearing in NEET-SS 2024 from candidates who are qualifying and/or getting the results of their MD/MS/DNB qualifications/eligible feeder qualifications after 30th April 2025 shall be summarily rejected.

5 Registration with NMC/State Medical Council is mandatory and its documentary proof should be furnished at the test Centre on the examination day.

6 Foreign Nationals including Overseas Citizen of India (OCI) cardholders can appear in NEET-SS 2024 without registration with the National Medical Commission (NMC). The NMC may, on payment of the prescribed fee for registration, grant temporary registration for the duration of the post-doctoral course limited to the medical college/institution to which he/she is admitted for the time being exclusively for pursuing postdoctoral studies. Provided further that temporary registration to such foreign national shall be subject to the condition that such person is duly registered with appropriate registering authority in his/her own country where he has obtained his PG Medical qualification and is duly recognised by the corresponding Medical Council or concerned authority.

7 Candidates already pursuing or have joined a Doctoral Course (DM/MCh/DrNB) through NEET-SS are not eligible for admission to DrNB Superspecialty courses through NEET-SS 2024 for the entire duration prescribed for the course already joined by them earlier. This shall be irrespective of their resignation or discontinuation from the said course due to any reason.

8 The FCPS qualifications awarded by the College of Physicians and Surgeons, Mumbai are not equivalent to either MD or MS courses. Accordingly, candidates possessing FCPS qualifications awarded by the College of Physicians and Surgeons, Mumbai are not eligible to apply for NEET-SS, solely based on their FCPS qualifications.

9 Eligibility of candidates issued admit card for the examination shall be purely provisional. Appearing in NEET-SS 2024 does not confer any automatic rights upon the candidate for admission to DM/MCh/DrNB Super Specialty courses.

Examination Fee

Examination Fee per Group*

Rs. 3500

*Excluding charges as may be applicable by various payment gateways. GST has been EXEMPTED as per Department of Revenue, Ministry of Finance, Govt of India circular no 151/07/2021-GST dated 17.06.2021

Candidate shall be required to pay the examination fee as mentioned above for each group in which he/she chooses to appear. For eg. A candidate with MD Paediatrics qualification who chooses to appear in question papers for both Medical and Paediatric Groups shall be required to pay Rs. 3500 + 3500 = 7000/- towards examination fee. Please refer chapter on details of scheme of examination

Applications forms once submitted cannot be withdrawn. Fee shall neither be carried forward to a future date nor refunded under any circumstances. Application once submitted cannot be withdrawn. Any claim for refund, adjustment or carrying forward of Application fee will not be entertained.

How to pay: The prescribed exam fee should be remitted through payment gateway provided using a Credit Card or a Debit Card issued by banks in India or other modes as may be made available and have been provided on the web page. Fee can not be deposited through any mode other than the payment gateway available while submitting online application form submission.

Examination fees in respect of candidates who are absent or have been declared ineligible due to any reason will be forfeited. Candidates are advised to read the information bulletin for NEET SS 2024 carefully and pay examination fee only if they fulfil eligibility criteria prescribed in the bulletin.

Meanwhile, NBEMS will be conducting the NEET-SS 2024 in two slots in 2 days on a computer-based platform at various exam centres across the country. Interested candidates can start submitting the application form for the NEET-SS 2024. Below is the complete schedule-

SCHEDULE

S.NO

PROCESSES

TIMELINES

1

Online Application Submission.

4th February 2025 (3 PM Onwards) to 24th February 2025 (Till 11:55 PM).

2

Edit Window for All Applicants.

27th February 2025 to 3rd March 2025.

3

Final Edit Window to Rectify Deficient/Incorrect Images (No further opportunity shall be given)

1 Photograph.

2 Signatures.

3 Thumb Impression.

11th March 2025 to 13th March 2025.

4

Issue of Admit Card.

25th March 2025.

5

Examination Date.

29th & 30th March 2025.

6

Cut Off Date for qualifying MD/ MS/DNB Broad Specialty qualification towards determination of eligibility for appearing in NEET-SS 2024.

30th April 2025.

7

Declaration of Result.

By 30th April 2025.

Powered by WPeMatico

Pressure to seem perfect can strain teen relationships, but kindness from peers can help

Imagine trying to always appear perfect. You stay on top of the latest beauty trends, excel academically and project confidence in social settings, even when you’re struggling or feeling completely overwhelmed. You work hard to hide any potential flaws, constantly worrying that if you stumble or show any cracks in your armor, everything will fall apart.

Powered by WPeMatico

Should babies get a ‘bonus dose’ of the measles vaccine? Doctors say it depends

Like many anxious parents, Beth Spektor spent the last few weeks fretting over how to protect her infant daughter from the first deadly measles outbreak to hit the U.S. in a decade.

Powered by WPeMatico

3D-printed tissue restores erectile function and aids reproduction in animal study

Erectile dysfunction affects over 40% of men over 40, yet our understanding of the condition remains limited. Research on this issue has mostly relied on real organs, making it difficult to study the detailed interaction between blood flow and tissue during an erection.

Powered by WPeMatico

No evidence for ‘wind turbine syndrome’ claims: Windmill noise is no more stressful than traffic sounds, study suggests

A team of cognitive neuroscientists and acoustic engineers at Adam Mickiewicz University, in Poland, has found no evidence that wind turbine noise causes mental impairment. In their study, published in the journal Humanities and Social Sciences Communication, the group conducted experiments exposing human volunteers to various noises and measured a range of impacts.

Powered by WPeMatico

Can melatonin supplements really ‘reverse’ DNA damage caused by lack of sleep?

Sleep isn’t just a luxury, it’s a vital process that helps our bodies repair and rejuvenate. Researchers have started to uncover how the quality and timing of sleep can affect more than just how rested we feel—it might also affect the very blueprint of our cells: our DNA.

Powered by WPeMatico